Prescribing information available here
Adverse event reporting information can be found at the bottom of this page
Patients switching to Easyhaler® are more likely to achieve overall disease control, have improved quality of life, and they are also more satisfied with their inhaler compared to their previous inhaler device.1,2 Patient satisfaction with their inhaler is associated with higher adherence and improved asthma control. 1–3
ASTHMA CONTROL AFTER SWITCHING TO
BUFOMIX (BUDESONIDE FORMOTEROL) EASYHALER4
Bufomix Easyhaler Contraindications and Undesirable effects
Contraindications: Hypersensitivity to the active substances or lactose monohydrate (which contains small amounts of milk protein).
Undesirable effects:
Common (≥1/100 to < 1/10): Candida infections in the oropharynx, pneumonia (in COPD patients) headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.
See SmPC for full list of adverse reactions
Date of preparation: October 2024 / EASYH-2725(1)
References
- Tamasi L, Szilasi M, Gálffy G. Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler®, for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes. Adv Ther. 2018;35:1140–1152.
- Gálffy G, Szilasi M, Tamási L. Effectiveness and patient satisfaction with budesonide/formoterol Easyhaler® among patients with asthma or COPD switching from previous treatment: a real-world study of patient-reported outcomes. Pulm Ther. 2019;5:165-177.
- Plaza V, Giner J, Calle M, Rytilä P, Campo C, Ribó P, Valero A. Impact of patient satisfaction with his or her inhaler on adherence and asthma control. Allergy Asthma Proc. 2018 Nov 18;39(6):437-444.
- Syk J, Vinge I, Sörberg M, Vahteristo M, Rytilä P. A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler®.Adv Ther 2019. [Epub ahead of print]
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
| Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com |
